ArticleWorld journal of nuclear medicine2026
A Novel Non-Invasive Diagnostic Tool for Determining the Subtype of Primary Aldosteronism Using
Article in World journal of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary aldosteronism (PA) may present as either unilateral or bilateral disease. Differentiating unilateral forms-unilateral aldosterone- producing adenoma (APA) and unilateral adrenal hyperplasia-from bilateral forms-bilateral APA, bilateral adrenal hyperplasia (BAH)-is critical, as the management strategies differ. Currently, PA subtyping is performed using adrenal vein sampling (AVS) and computed tomography (CT). However, AVS is invasive and technically demanding, and CT has limited accuracy. CXCR4 (CXC chemokine receptor type 4) expression is higher in APAs than in normal adrenal tissue and non-functional tumors. Pentixafor, a CXCR4-specific ligand labelled with Materials and Methods: This prospective observational study included 13 patients with confirmed PA who underwent Results: Among the 13 patients with PA, 10 were diagnosed with unilateral primary aldosteronism (UPA) and three with bilateral primary aldosteronism (BPA) based on Conclusion:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.